Dihexa

Most Common Uses

Dihexa finds its primary use in research exploring treatments for neurodegenerative conditions. Scientists investigate its ability to enhance cognitive function, particularly in animal models of Alzheimer’s disease, where it promotes memory and learning. Its potent neurotrophic effects, surpassing those of brain-derived neurotrophic factor, make it a candidate for studying neural repair and synaptic plasticity. Researchers also explore Dihexa’s potential in addressing cognitive deficits linked to aging or brain injury, leveraging its high-affinity binding to hepatocyte growth factor to stimulate neuroregeneration.

Mechanism of Action

Dihexa exerts its effects through high-affinity binding to hepatocyte growth factor (HGF), enhancing its interaction with the c-Met receptor. This binding amplifies HGF-dependent signaling pathways, promoting cell growth, survival, and differentiation in neural tissues. Dihexa’s neurotrophic activity, significantly more potent than brain-derived neurotrophic factor, supports synaptic plasticity and neurogenesis. In preclinical studies, it enhances dendritic spine density and improves cognitive function in animal models of neurodegenerative diseases. Its ability to cross the blood-brain barrier further enables direct influence on neural repair and cognitive processes.

Structure and Pharmacology

Dihexa’s chemical structure consists of a hexanoyl group attached to a tyrosine-isoleucine dipeptide, followed by a 6-aminohexanoic amide. The molecular formula is C27H44N4O5, with a molecular weight of 504.7 g/mol. This compact structure enables Dihexa to cross the blood-brain barrier efficiently, a feature that supports its activity in neural tissues. Its design enhances stability and receptor-binding affinity compared to its parent compound.

Pharmacologically, Dihexa acts primarily through high-affinity binding to hepatocyte growth factor (HGF), amplifying its interaction with the c-Met receptor. This interaction stimulates signaling pathways that promote cell growth, survival, and differentiation, particularly in neurons. Dihexa exhibits potent neurotrophic effects, surpassing brain-derived neurotrophic factor in supporting synaptic plasticity and neurogenesis. In animal studies, it increases dendritic spine density and enhances cognitive performance, especially in models of neurodegenerative conditions like Alzheimer’s disease.

Its long half-life, approximately 12.7 days following intravenous administration and 8.8 days after intraperitoneal administration in rats, supports sustained activity. Dihexa’s ability to penetrate the blood-brain barrier allows direct influence on neural repair and cognitive function, making it a promising candidate for neurodegenerative research.

Dosages

Dihexa remains primarily a research compound, and standardized human dosages have not been established due to limited clinical trials. In preliminary studies, particularly with animal models, it depends on the route of administration and study design. Oral administration in rats typically involves doses ranging from 2 to 10 mg/kg body weight daily, often dissolved in a vehicle like dimethyl sulfoxide (DMSO) or saline to enhance bioavailability. Intraperitoneal injections in similar models use doses between 1 and 4 mg/kg, administered every few days, leveraging Dihexa’s long half-life of approximately 8 to 12 days. Researchers adjust these doses to optimize neurotrophic and cognitive effects while monitoring for potential side effects. Human applications remain exploratory, and no regulatory body has approved Dihexa for clinical use, so dosing in humans lacks formal guidelines.

Warnings and Cautions

Dihexa is still an experimental peptide, mostly explored in preclinical settings, and its usage in people has not been approved by regulatory agencies such as the FDA. Limited data on human safety and long-term effects necessitate caution. Animal studies suggest potential benefits for cognitive function and neural repair, but side effects, including possible overstimulation of neural growth pathways, remain understudied. Researchers handling Dihexa should use appropriate protective measures, as its high potency and ability to cross the blood-brain barrier may pose unknown risks. People considering Dihexa for non-research purposes face uncertainties due to the absence of clinical trials establishing safe dosage, efficacy, or interactions with other medications. Consultation is essential before any experimental use. Pregnant or breastfeeding women should avoid exposure, as no studies evaluate Dihexa’s effects on fetal or infant development.

Research & Clinical Trials

The Development of Angiotensin IV Analogs to Treat Alzheimer’s and Parkinson’s Diseases

The study found that current treatments for Alzheimer’s and Parkinson’s disease don’t do much to stop the real issue, brain cells and their connections slowly dying off. The researchers said we need new kinds of peptides that go beyond the standard used today, which don’t fix the root cause.

They looked into a part of the brain called the RAS (renin-angiotensin system), focusing on  angiotensin IV and how it works with the AT4 receptor. Scientists still aren’t totally sure what the AT4 receptor is, but it might be either a protein called IRAP or part of another system called the HGF/c-Met pathway. Either way, peptides based on AngIV seem promising because they can get into the brain and are more stable than earlier versions.

One of these peptides, called Dihexa, stood out. It helped improve memory and movement in disease models, probably by helping the brain grow new connections between cells (a process called synaptogenesis). Because of this, the study suggests that Dihexa could become an effective treatment for brain diseases like AD and PD by helping restore lost brain function. [1]

Cognitive Benefits of Angiotensin IV and Angiotensin-(1-7) 

This review found that turning on certain parts of the brain’s renin-angiotensin system (RAS), especially using protein-like molecules called Angiotensin IV (Ang IV) and Angiotensin-(1–7) [Ang-(1–7)] and their matching receptors (AT4R and Mas), can help boost memory and learning, particularly in animals with memory problems. In healthy animals, Ang IV often helped with tasks involving memory and recognizing objects. In animals that showed signs of Alzheimer’s disease, Ang IV and its more stable versions (like Dihexa and Nle1-Ang IV) regularly improved short-term memory and learning. Ang-(1–7) also helped with memory, and this was tied to how the Mas receptor worked.

These memory improvements worked best when the substances were given straight into the brain, right around the time of learning or memory tests. The results support the idea that the brain’s own RAS system plays an important role in thinking and memory, and it might be a useful focus for future Alzheimer’s treatments. Still, challenges like the substances not easily getting into the brain and not fully understanding how they work have slowed down progress, but newer versions like Dihexa might help solve those problems. [2]

Rescues Cognitive Impairment and Recovers Memory

In a 2024 preclinical study, Dihexa demonstrated significant therapeutic potential for Alzheimer’s disease by improving cognitive performance and reducing neurodegeneration in APP/PS1 transgenic mice, a commonly used animal model for studying the disease. Dihexa, an orally active analog of angiotensin IV that can cross the blood–brain barrier, was shown to restore reduced levels of AngIV in the brains of Alzheimer’s model mice. This restoration correlated with enhanced performance in the Morris water maze test, indicating improvements in spatial learning and memory. Beyond just improving behavior, Dihexa treatment led to an increase in healthy brain cells and boosted levels of synaptophysin, a protein important for communication between neurons. This points to better connections and flexibility in the brain. The study also found that Dihexa greatly reduced brain inflammation by calming down support cells in the brain (astrocytes and microglia) and balancing chemical signals, lowering harmful ones like IL-1β and TNF-α, while raising helpful ones like IL-10. These benefits were tied to the activation of a cell-protecting pathway in the brain called PI3K/AKT, which helps keep brain cells alive and functioning. When researchers blocked this pathway using a substance called wortmannin, Dihexa’s positive effects were noticeably reduced, confirming that this pathway plays a key role in how the peptide works. Altogether, these results suggest that Dihexa could be a strong new treatment option for reducing brain inflammation, improving brain cell connections, and slowing memory loss in Alzheimer’s disease. [3]